Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of (S)-Disopyramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Disopyramide SCHEMBL23931452 | 1.00 | KCNH2 (1.00) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL16153 | 1.00 | KCNH2 (1.00) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL546251 | 0.99 | KCNH2 (0.98) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL9097836 | 0.96 | KCNH2 (0.93) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL41810 | 0.95 | KCNH2 (0.91) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL5167606 | 0.95 | KCNH2 (0.91) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL8511308 | 0.94 | KCNH2 (0.89) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| SCHEMBL10945741 | 0.93 | KCNH2 (0.87) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| Disopyramide SCHEMBL20770785 | 0.92 | KCNH2 (0.85) | KCNH2BLMOPRK1SLC22A2SLC22A1 | |
| SCHEMBL10798660 | 0.92 | KCNH2 (0.85) | KCNH2BLMOPRK1SLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3094 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038939-A9 | POROUS PELLETS AND PROCESS OF MANUFACTURING THE SAME | SPI PHARMA, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025038939-A1 | POROUS PELLETS AND PROCESS OF MANUFACTURING THE SAME | SPI PHARMA, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4066850-A2 | PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAME | Bioincept LLC (US) | 2022-10-05 | — | — | EP | claimed |
| EP-3509607-A1 | FORMULATION FOR PREVENTING OR TREATING DENTIN-ASSOCIATED SYMPTOMS OR DISEASES, AND METHOD USING THE SAME | Sancastle Worldwide Corporation (TW) | 2019-07-17 | — | — | EP | claimed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| CN-108064157-A | Formulations for preventing or treating dentinal tubule associated symptoms or diseases and methods of use thereof | 圣凯瑟世界股份有限公司 | 2018-05-22 | — | — | CN | claimed |
| WO-2018046978-A1 | FORMULATION FOR PREVENTING OR TREATING DENTIN-ASSOCIATED SYMPTOMS OR DISEASES, AND METHOD USING THE SAME | SANCASTLE WORLDWIDE CORPORATION (TW) | 2018-03-15 | — | — | WO | claimed |
| US-20180064757-A1 | FORMULATION FOR PREVENTING OR TREATING DENTIN-ASSOCIATED SYMPTOMS OR DISEASES, AND METHOD USING THE SAME | SANCASTLE WORLDWIDE CORPORATION (TW) | 2018-03-08 | — | — | US | claimed |
| US-20170304388-A1 | NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION | LAUNX BIOMEDICAL CO., LTD. (TW) | 2017-10-26 | — | — | US | claimed |
| US-5166142-A | Anticholesterol agents such as quinidine, procainamide or disopyramide | UNIVERSITY OF ROCHESTER (US) | 1992-11-24 | — | — | US | claimed |
| US-5026559-A | Multilayer walled coating | KINAFORM TECHNOLOGY, INC. (US) | 1991-06-25 | — | — | US | claimed |
| EP-0425659-A1 | SUSTAINED RELEASE PHARMACEUTICAL PREPARATIONS HAVING pH CONTROLLED MEMBRANE COATINGS. | KINAFORM TECHNOLOGY INC (US) | 1991-05-08 | — | — | EP | claimed |
| US-4983401-A | Sustained release pharmaceutical preparations having pH controlled membrane coatings | KINAFORM TECHNOLOGY, INC. (US) | 1991-01-08 | — | — | US | claimed |
| WO-1990014077-A1 | SUSTAINED RELEASE PHARMACEUTICAL PREPARATIONS HAVING pH CONTROLLED MEMBRANE COATINGS | KINAFORM TECHNOLOGY, INC. (US) | 1990-11-29 | — | — | WO | claimed |
| EP-0391518-A2 | Sustained-release pharmaceutical preparation | KINAFORM TECHNOLOGY, INC. (US) | 1990-10-10 | — | — | EP | claimed |
| US-4789549-A | IN A WATER SOLUBLE POLYMER MATRIX COATED WITH POLYMERIC SEMIPERMEABLE MEMBRANE | WARNER-LAMBERT COMPANY (US) | 1988-12-06 | — | — | US | claimed |
| EP-0282011-A2 | Sustained release pharmaceutical dosage forms | WARNER-LAMBERT COMPANY (US) | 1988-09-14 | — | — | EP | claimed |
| EP-0239361-A1 | Sustained-release pharmaceutical preparation | KINAFORM TECHNOLOGY, INC. (US) | 1987-09-30 | — | — | EP | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |